Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (71-80 of 255) with videos related to

Pageof 26
Sort By:
Frontiers in Oncology|September 8, 2023
The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, CanadaCraig A Beers, Gregory R Pond, James R Wright, et al.
Urologic Oncology|May 4, 2012
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trialsGregory R Pond, Andrew J Armstrong, Matthew D Galsky, et al.
American Journal of Clinical Oncology|November 4, 2009
The contents and readability of informed consent forms for oncology clinical trialsWinson Y Cheung, Gregory R Pond, Ronald J Heslegrave, et al.
Clinical Genitourinary Cancer|September 25, 2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancerGregory R Pond, William R Berry, Matthew D Galsky, et al.
Gynecologic Oncology|March 6, 2022
The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancersKara L Schnarr, Hsien Seow, Gregory R Pond, et al.
Urologic Oncology|May 21, 2013
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancerJatinder Goyal, Gregory R Pond, Matthew D Galsky, et al.
BMC Cancer|February 10, 2006
Understanding the attitudes of the elderly towards enrolment into cancer clinical trialsCarol A Townsley, Kelvin K Chan, Gregory R Pond, et al.
Journal of the National Cancer Institute|July 5, 2012
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic reviewJulien Péron, Gregory R Pond, Hui K Gan, et al.
Breast Cancer Research and Treatment|July 28, 2021
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort studyKatarzyna J Jerzak, Nechama Lipton, Sharon Nofech-Mozes, et al.
Gynecologic Oncology|March 22, 2021
The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?Kara L Schnarr, Hsien Seow, Lorraine M Elit, et al.
Pageof 26

Showing results (71-80 of 255) with videos related to

Sort By:
Pageof 26
Frontiers in Oncology|September 8, 2023
The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, CanadaCraig A Beers, Gregory R Pond, James R Wright, et al.
Urologic Oncology|May 4, 2012
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trialsGregory R Pond, Andrew J Armstrong, Matthew D Galsky, et al.
American Journal of Clinical Oncology|November 4, 2009
The contents and readability of informed consent forms for oncology clinical trialsWinson Y Cheung, Gregory R Pond, Ronald J Heslegrave, et al.
Clinical Genitourinary Cancer|September 25, 2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancerGregory R Pond, William R Berry, Matthew D Galsky, et al.
Gynecologic Oncology|March 6, 2022
The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancersKara L Schnarr, Hsien Seow, Gregory R Pond, et al.
Urologic Oncology|May 21, 2013
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancerJatinder Goyal, Gregory R Pond, Matthew D Galsky, et al.
BMC Cancer|February 10, 2006
Understanding the attitudes of the elderly towards enrolment into cancer clinical trialsCarol A Townsley, Kelvin K Chan, Gregory R Pond, et al.
Journal of the National Cancer Institute|July 5, 2012
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic reviewJulien Péron, Gregory R Pond, Hui K Gan, et al.
Breast Cancer Research and Treatment|July 28, 2021
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort studyKatarzyna J Jerzak, Nechama Lipton, Sharon Nofech-Mozes, et al.
Gynecologic Oncology|March 22, 2021
The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?Kara L Schnarr, Hsien Seow, Lorraine M Elit, et al.
Pageof 26